← SWS Hemodialysis Care Co. Ltd. A overview

SWS Hemodialysis Care Co. Ltd. A vs Guangzhou Wondfo Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

SWS Hemodialysis Care Co. Ltd. A (688410.CG)

Q3 202622 Jul – 28 Aug 2026

▲3▼1

Strong H1 profit and new product approvals offset major shareholder selling

H1 profit jumps 71% on higher sales and margins SWS reported first-half 2026 revenue up 29.8% to 464 million yuan and net profit up 71.46% to 94.37 million yuan. Higher sales of self-made blood purification consumables and better gross margin drove the gain, showing the core business is growing profitably.
This is the main positive force behind the stock, showing strong underlying business momentum.
New product approvals expand market access A subsidiary received a medical device registration certificate for single-use hemodialysis blood tubing and a change filing for continuous blood purification tubing. These approvals let SWS sell more products in hospitals, supporting future revenue growth.
New product approvals are a concrete growth driver that can lift future sales and investor confidence.
High dividend payout signals confidence and cash returns SWS plans to pay 2 yuan per 10 shares, a 94.83% payout of first-half profit. A high dividend returns cash to shareholders and signals management's confidence in steady earnings, which can attract income-focused investors.
The dividend is a new capital return event that supports the stock's appeal and shows financial health.
Major shareholder plans to sell up to 4.03% stake A major shareholder plans to cut its stake by up to 4.03%, worth about 200 million yuan, starting September 3. This is the third reduction plan in a year, which can pressure the stock price by increasing the number of shares for sale.
This is the main counterweight to the positive news, explaining why the stock may face selling pressure.

August 202622 Jul – 28 Aug 2026

▲3▼1

Strong H1 profit and new product approvals offset major shareholder selling

H1 profit jumps 71% on higher sales and margins SWS reported first-half 2026 revenue up 29.8% to 464 million yuan and net profit up 71.46% to 94.37 million yuan. Higher sales of self-made blood purification consumables and better gross margin drove the gain, showing the core business is growing profitably.
This is the main positive force behind the stock, showing strong underlying business momentum.
New product approvals expand market access A subsidiary received a medical device registration certificate for single-use hemodialysis blood tubing and a change filing for continuous blood purification tubing. These approvals let SWS sell more products in hospitals, supporting future revenue growth.
New product approvals are a concrete growth driver that can lift future sales and investor confidence.
High dividend payout signals confidence and cash returns SWS plans to pay 2 yuan per 10 shares, a 94.83% payout of first-half profit. A high dividend returns cash to shareholders and signals management's confidence in steady earnings, which can attract income-focused investors.
The dividend is a new capital return event that supports the stock's appeal and shows financial health.
Major shareholder plans to sell up to 4.03% stake A major shareholder plans to cut its stake by up to 4.03%, worth about 200 million yuan, starting September 3. This is the third reduction plan in a year, which can pressure the stock price by increasing the number of shares for sale.
This is the main counterweight to the positive news, explaining why the stock may face selling pressure.

Latest22 Jul – 28 Aug 2026

▲3▼1

Strong H1 profit and new product approvals offset major shareholder selling

H1 profit jumps 71% on higher sales and margins SWS reported first-half 2026 revenue up 29.8% to 464 million yuan and net profit up 71.46% to 94.37 million yuan. Higher sales of self-made blood purification consumables and better gross margin drove the gain, showing the core business is growing profitably.
This is the main positive force behind the stock, showing strong underlying business momentum.
New product approvals expand market access A subsidiary received a medical device registration certificate for single-use hemodialysis blood tubing and a change filing for continuous blood purification tubing. These approvals let SWS sell more products in hospitals, supporting future revenue growth.
New product approvals are a concrete growth driver that can lift future sales and investor confidence.
High dividend payout signals confidence and cash returns SWS plans to pay 2 yuan per 10 shares, a 94.83% payout of first-half profit. A high dividend returns cash to shareholders and signals management's confidence in steady earnings, which can attract income-focused investors.
The dividend is a new capital return event that supports the stock's appeal and shows financial health.
Major shareholder plans to sell up to 4.03% stake A major shareholder plans to cut its stake by up to 4.03%, worth about 200 million yuan, starting September 3. This is the third reduction plan in a year, which can pressure the stock price by increasing the number of shares for sale.
This is the main counterweight to the positive news, explaining why the stock may face selling pressure.

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Q3 202625 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.

August 202625 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.

Latest25 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.